Efficacy

Enhertu (fam-trastuzumab deruxtecan-nxki) for Gastric Cancer

Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate that has shown efficacy in the treatment of HER2-positive gastric or gastroesophageal junction (GEJ) cancer. It is specifically designed to target and deliver chemotherapy directly to cancer cells that overexpress HER2, a protein that can promote the growth of cancer cells. In clinical trials, Enhertu has demonstrated significant improvements in overall survival and progression-free survival compared to standard treatments. For instance, the pivotal Phase 2 trial, DESTINY-Gastric01, showed that patients treated with Enhertu had a median overall survival of 12.5 months compared to 8.4 months for those treated with chemotherapy alone.

The efficacy of Enhertu in gastric cancer was further supported by the results of the Phase 3 DESTINY-Gastric02 trial, which confirmed the survival benefit and showed a higher objective response rate in patients receiving Enhertu. The drug has received approval in several countries for use in patients with unresectable or metastatic HER2-positive gastric or GEJ cancer who have previously received a trastuzumab-based regimen. This approval marks a significant advancement in the treatment options available for this aggressive form of cancer.

Jeselhy (pimitespib) for Gastric Cancer

Jeselhy (pimitespib) is a novel therapeutic agent under investigation for the treatment of gastric cancer. It is a heat shock protein 90 (HSP90) inhibitor, which plays a role in the stabilization and proper function of various proteins that are essential for the growth and survival of cancer cells. By inhibiting HSP90, Jeselhy aims to disrupt these processes and exert antitumor effects. While Jeselhy is still in the clinical development stages, early trial results have shown promise in the treatment of advanced gastric cancer, particularly in patients who have exhausted other treatment options.

For example, in early-phase clinical studies, Jeselhy has demonstrated a manageable safety profile and preliminary signs of efficacy in patients with gastric cancer. The ongoing research is focused on determining the optimal dosing, understanding the spectrum of its activity against various gastric cancer subtypes, and evaluating its efficacy in combination with other therapies. As of the current knowledge cutoff, Jeselhy continues to be studied, and further results from clinical trials are awaited to establish its potential role in the treatment landscape of gastric cancer.